Stockscreener 앱 받기
502.48
0.32%
1.325
Vertex Pharmaceuticals Inc 주식(VRTX)의 최신 뉴스
Vertex Abandons AAV as Gene Therapy Space Weathers Difficulties - BioSpace
3 No-Brainer Stocks to Buy in May - The Motley Fool
Gilead and Vertex Pharma named among biotech’s tariff safe havens - MSN
How Will Vertex Pharmaceuticals Stock React To Its Upcoming Earnings? - Nasdaq
Vertex Pharmaceuticals (VRTX) Earnings Preview: What to Expect - GuruFocus
Vertex discontinues AAV research for gene therapies - Fierce Biotech
As Journavx rollout begins, Vertex kicks off unbranded pain campaign with NFL alum Alex Smith - Fierce Pharma
Vertex Pharmaceuticals (VRTX) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Final Trades: Berkshire Hathaway, Vertex Pharma, S&P Global and CME Group - MSN
What Analyst Projections for Key Metrics Reveal About Vertex (VRTX) Q1 Earnings - Nasdaq
Vertex Gears Up to Report Q1 Earnings: Is a Beat in the Cards? - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo Finance
European regulators recommend new drugs from Vertex, Amgen and Jazz - Endpoints News
, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis - Business Wire
Press Release Distribution & PR Platform - ACCESS Newswire
US Health Secretary Reportedly Says 35 States to Join Pilot Program for Sickle Cell Disease Gene Therapies - marketscreener.com
EMA Backs Vertex Pharmaceuticals' (VRTX) Alyftrek for Cystic Fib - GuruFocus
Vertex’s Alyftrek For CF Among Six Orphans On Track For Pan-EU Approval - insights.citeline.com
Vertex Pharmaceuticals Stock (VRTX) Trending as Q1 Earnings Approach - TipRanks
Vertex Pharmaceuticals (VRTX) Advances But Underperforms Market: Key Facts - Yahoo Finance
Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday - MSN
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - MSN
Vertex Pharmaceuticals’ Q1 2025 Earnings: What to Expect - Nasdaq
Vertex Pharmaceuticals’ Q1 2025 Earnings: What To Expect - Barchart.com
Eli Lilly, Vertex, AbbVie and More Pharma Stocks to Own as Tariffs Loom - MSN
Eli Lilly, Vertex, AbbVie, and More Pharma Stocks to Own as Tariffs Loom - Barron's
Vertex Pharmaceuticals (VRTX) Gains Favor with Increased Price T - GuruFocus
Expert Outlook: Vertex Pharmaceuticals Through The Eyes Of 18 Analysts - Benzinga
Vertex Pharmaceuticals (VRTX) Gains Favor with Increased Price Target | VRTX Stock News - GuruFocus
ToolGen sues Vertex over alleged unlicensed use of CRISPR tech in gene therapy - koreabiomed.com
Vertex Has A Lot Riding On Alyftrek, Journavx — And Investors Are Watching Closely - Benzinga
Vertex Pharmaceuticals (NasdaqGS:VRTX) Faces UK Patent Lawsuit Over Groundbreaking CASGEVY Therapy - simplywall.st
ToolGen Files Patent Infringement Lawsuit Against Vertex in the United Kingdom - Longview News-Journal
Lobbying Update: $1,600,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed - Nasdaq
Reshma Kewalramani Among TIME’s 100 Most Influential People Of 2025 - IndiaWest
Reshma Kewalramani among 2025 Time 100 most influential people - The American Bazaar
Peering Into Vertex Pharmaceuticals's Recent Short Interest - Benzinga
Reshma Kewalramani named among Time magazine's 100 most influential people - Firstpost
Vertex’s Attempt to Redefine AKS Falls Short: Key Insights for Pharma Manufacturers - ArentFox Schiff
Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $617 From $615, Maintains Buy Rating - marketscreener.com
Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis - BioSpace
Vertex Pharmaceuticals (VRTX) Celebrated for Groundbreaking CF R - GuruFocus
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals? - AOL.com
Lobbying Update: $20,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed - Nasdaq
0.10%
0.93%
자본화:
|
볼륨(24시간):